Pernod Ricard (RI.PA) is rated a sell due to persistently weak operational results and an expensive valuation, even after ...
Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results